113 related articles for article (PubMed ID: 36485070)
1. Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial.
Xiang L; Shen L; Chen Y; Guo Y; Jiang R; Zhang W; Jia H; Wu Z; Zang R
BJOG; 2022 Nov; 129 Suppl 2():32-39. PubMed ID: 36485070
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract][Full Text] [Related]
3. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
Shi T; Jiang R; Yu J; Yang H; Tu D; Dai Z; Shen Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
Br J Cancer; 2018 Jul; 119(1):12-18. PubMed ID: 29899395
[TBL] [Abstract][Full Text] [Related]
4. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Shi T; Jiang R; Pu H; Yang H; Tu D; Dai Z; Cai Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
Br J Cancer; 2019 Aug; 121(5):425-428. PubMed ID: 31383985
[TBL] [Abstract][Full Text] [Related]
5. Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
Manning-Geist BL; Sullivan MW; Sarda V; Gockley AA; Del Carmen MG; Matulonis U; Growdon WB; Horowitz NS; Berkowitz RS; Clark RM; Worley MJ
Ann Surg Oncol; 2021 Oct; 28(11):6705-6713. PubMed ID: 33683525
[TBL] [Abstract][Full Text] [Related]
6. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
7. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
Chambers LM; Son J; Radeva M; DeBernardo R
J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
11. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
Lee J; Curtin JP; Muggia FM; Pothuri B; Boyd LR; Blank SV
Cancer Chemother Pharmacol; 2018 Jul; 82(1):55-63. PubMed ID: 29704010
[TBL] [Abstract][Full Text] [Related]
12. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
[TBL] [Abstract][Full Text] [Related]
13. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Le T; Latifah H; Jolicoeur L; Weberpals J; Faught W; Hopkins L; Fung MF
Gynecol Oncol; 2011 Jun; 121(3):451-4. PubMed ID: 21402403
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2011 Nov; (11):CD005340. PubMed ID: 22071822
[TBL] [Abstract][Full Text] [Related]
18. Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data.
Adambekov S; Lopa S; Edwards RP; Lemon L; Wang S; Taylor SE; Orr B; Linkov F
Cancer Med; 2020 Oct; 9(20):7388-7397. PubMed ID: 32813321
[TBL] [Abstract][Full Text] [Related]
19. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
